145 related articles for article (PubMed ID: 31263157)
1. TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.
Niwa N; Tanaka N; Hongo H; Miyazaki Y; Takamatsu K; Mizuno R; Kikuchi E; Mikami S; Kosaka T; Oya M
Lab Invest; 2019 Nov; 99(11):1702-1713. PubMed ID: 31263157
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT.
Guo Y; Jia Y; Wang S; Liu N; Gao D; Zhang L; Lin Z; Wang S; Kong F; Peng C; Liu Y
Oncol Rep; 2019 Dec; 42(6):2716-2727. PubMed ID: 31578574
[TBL] [Abstract][Full Text] [Related]
3. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
4. Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition.
Tseng WC; Chuang CW; Yang MH; Pan CC; Tarng DC
Urol Oncol; 2016 Nov; 34(11):485.e15-485.e24. PubMed ID: 27519276
[TBL] [Abstract][Full Text] [Related]
5. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
6. [Investigation of epithelial-mesenchymal transition induced by cisplatin on human laryngeal resistant cancer cells].
Gong XR; Yu F; Zhou YB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Dec; 31(23):1839-1843. PubMed ID: 29798399
[No Abstract] [Full Text] [Related]
7. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
8. Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.
Tanaka N; Kosaka T; Miyazaki Y; Mikami S; Niwa N; Otsuka Y; Minamishima YA; Mizuno R; Kikuchi E; Miyajima A; Sabe H; Okada Y; Uhlén P; Suematsu M; Oya M
JCI Insight; 2016 Nov; 1(18):e83654. PubMed ID: 27812537
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
10. Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells.
Mao Z; Wu Y; Zhou J; Xing C
Anticancer Drugs; 2019 Oct; 30(9):892-899. PubMed ID: 30882398
[TBL] [Abstract][Full Text] [Related]
11. Nkx2.8 Inhibits Epithelial-Mesenchymal Transition in Bladder Urothelial Carcinoma via Transcriptional Repression of
Yu C; Liu Z; Chen Q; Li Y; Jiang L; Zhang Z; Zhou F
Cancer Res; 2018 Mar; 78(5):1241-1252. PubMed ID: 29311157
[TBL] [Abstract][Full Text] [Related]
12. miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma.
Liu M; Wang J; Huang H; Hou J; Zhang B; Wang A
Biochem Biophys Res Commun; 2013 Nov; 441(2):364-70. PubMed ID: 24148247
[TBL] [Abstract][Full Text] [Related]
13. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
14. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
15. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines.
Dong P; Kaneuchi M; Watari H; Sudo S; Sakuragi N
Mol Carcinog; 2014 May; 53(5):349-59. PubMed ID: 24002805
[TBL] [Abstract][Full Text] [Related]
18. Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1.
Pei XH; Lv XQ; Li HX
Biochem Biophys Res Commun; 2014 Mar; 446(1):322-7. PubMed ID: 24607904
[TBL] [Abstract][Full Text] [Related]
19. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer.
Yang Y; Wang G; Zhu D; Huang Y; Luo Y; Su P; Chen X; Wang Q
Int J Oncol; 2017 Aug; 51(2):515-524. PubMed ID: 28627611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
